|
公司基本資料信息
|
F-0901 | Neuropeptide AF (human) A-18-F-amide (human), NPAF (human) |
C90H132N26O25 | 1978.20 | 192387-38-5 | H-Ala-Gly-Glu-Gly-Leu-Asn-Ser-Gln-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2 |
F-0902 | Neuropeptide SF (human) | C65H94N18O15? | 1367.57 | 192387-39-6 | H-Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 Trifluoroacetate salt? |
F-0903 | Neuropeptide VF (56-92) (human) NPSF, S-37-F-NH2 |
C195H304N52O51S2? | 4257.01 | ? | H-Ser-Leu-Asn-Phe-Glu-Glu-Leu-Lys-Asp-Trp-Gly-Pro-Lys-Asn-Val-Ile-Lys-Met-Ser-Thr-Pro-Ala-Val-Asn-Lys-Met-Pro-His-Ser-Phe-Ala-Asn-Leu-Pro-Leu-Arg-Phe-NH2 |
F-0904 | Neuropeptide VF (124-131) (human) V-8-F-NH2, NPVF |
C45H72N14O10? | 969.16 | 311309-27-0 | H-Val-Pro-Asn-Leu-Pro-Gln-Arg-Phe-NH2 |
F-0905 | RFRP-3 (rat), Neuropeptide VF Precursor (108-125) amide (rat), RFamide-Related Peptide 2 (rat) | C88H134N26O25S2? | 2020.32 | 420088-80-8 | H-Ala-Asn-Met-Glu-Ala-Gly-Thr-Met-Ser-His-Phe-Pro-Ser-Leu-Pro-Gln-Arg-Phe-NH2 |
F-1001 | FA-Ala-Arg-OH | C16H23N5O5? | 365.39 | 76079-06-6 | FA-Ala-Arg-OH |
F-1002 | FA-Ala-Lys-OH | C16H23N3O5? | 337.38 | 76079-03-3 | FA-Ala-Lys-OH |
F-1003 | FA-Ala-Phe-NH2 | C19H21N3O4? | 355.39 | 29268-00-6 | FA-Ala-Phe-NH2 |
F-1004 | FA-Arg-Leu-OH | C19H29N5O5? | 407.47 | 158016-08-1 | FA-Arg-Leu-OH |
F-1005 | FA-Asp-Ala-OH | C14H16N2O7? | 324.29 | 196791-00-1 | FA-Asp-Ala-OH |